Cancer Research Cell Death Mechanisms and Cancer Therapy Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wechter, W. J.
Right arrow Articles by Greenberg, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wechter, W. J.
Right arrow Articles by Greenberg, N. M.
[Cancer Research 60, 2203-2208, April 15, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

E-7869 (R-Flurbiprofen) Inhibits Progression of Prostate Cancer in the TRAMP Mouse1

William J. Wechter2, Douglas D. Leipold, E. David Murray, Jr., David Quiggle, John D. McCracken, Robert S. Barrios and Norman M. Greenberg

Encore Pharmaceuticals Inc., Laboratory of Chemical Endocrinology, Loma Linda University, Loma Linda, California 92350 [W. J. W., D. D. L., E. D. M., D. Q.]; Division of Gastroenterology, Loma Linda Medical Center, Loma Linda, California 92350 [J. D. M.]; and Department of Cell Biology & Scott Department of Urology [N. M. G.], and Department of Pathology [R. S. B.], Baylor College of Medicine, Houston, Texas 77030

E-7869 (R-flurbiprofen) is a single enantiomer of a racemic nonsteroidal anti-inflammatory drug. E-7869 does not inhibit either cyclooxygenase-1 or cyclooxygenase-2. We used the transgenic adenocarcinoma mouse prostate (TRAMP) mouse, a prostate cancer model, to evaluate the effect of this drug on prostate cancer progression. Sixty 12-week-old male TRAMP mice were placed randomly into five groups. The animals were treated by daily oral gavage with vehicle (1% carboxymethylcellulose) or E-7869 for 18-weeks. During the course of the study, two diets were used. Three groups (vehicle, 15-mg/kg, and 20-mg/kg drug treatments) received a Teklad diet containing 2.4% saturated fat [a high saturated fat (HSF) diet], and two groups (vehicle and 20 mg/kg drug treatment) received an AIN-93G diet containing 1.05% saturated fat [a low saturated fat (LSF) diet]. At necropsy, the urogenital system and periaortic lymph nodes were removed and weighed. The prostate lobes, seminal vesicles, lungs, and periaortic lymph nodes were preserved and sectioned for histological evaluation. The lung and periaortic lymph nodes were graded as to the presence (+) or absence (-) of metastasis; the urogenital tissues were graded on a 1–6 scale for degree of neoplasia/carcinoma. For both diets, the urogenital wet weights and lymph node wet weights in the 20-mg/kg treatment groups were significantly lower as compared to vehicle control groups. In addition, treatment with 20 mg/kg E-7869 in the LSF diet group resulted in a significantly lower primary tumor incidence (P < 0.05) and reduced incidence of metastasis. In this treatment group, the reduced incidence of metastasis was not statistically significant because the LSF diet itself resulted in a remarkably lower incidence of metastasis in the vehicle control group (10% LSF versus 40% HSF). Treatment with 20 mg/kg E-7869 on the HSF diet resulted in a significantly lower incidence of metastasis (P < 0.05) and a reduction in the primary tumor incidence. These results suggest that E-7869 is a promising chemopreventive and treatment for human prostate cancer.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. A. Shafer-Weaver, S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, and A. A. Hurwitz
Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells
Cancer Res., August 1, 2009; 69(15): 6256 - 6264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. J. Quann, F. Khwaja, and D. Djakiew
The p38 MAPK Pathway Mediates Aryl Propionic Acid Induced Messenger RNA Stability of p75NTR in Prostate Cancer Cells
Cancer Res., December 1, 2007; 67(23): 11402 - 11410.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. E. Harper, B. B. Patel, J. Wang, A. Arabshahi, I. A. Eltoum, and C. A. Lamartiniere
Resveratrol suppresses prostate cancer progression in transgenic mice
Carcinogenesis, September 1, 2007; 28(9): 1946 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Huffman, W. E. Grizzle, M. M. Bamman, J.-s. Kim, I. A. Eltoum, A. Elgavish, and T. R. Nagy
SIRT1 Is Significantly Elevated in Mouse and Human Prostate Cancer
Cancer Res., July 15, 2007; 67(14): 6612 - 6618.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. M. Sargeant, R. D. Klein, R. C. Rengel, S. K. Clinton, S. K. Kulp, Y. Kashida, M. Yamaguchi, X. Wang, and C.-S. Chen
Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer
Toxicol Pathol, June 1, 2007; 35(4): 549 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. J. Quann, F. Khwaja, K. H. Zavitz, and D. Djakiew
The Aryl Propionic Acid R-Flurbiprofen Selectively Induces p75NTR-Dependent Decreased Survival of Prostate Tumor Cells
Cancer Res., April 1, 2007; 67(7): 3254 - 3262.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Anderson, K. Shafer-Weaver, N. M. Greenberg, and A. A. Hurwitz
Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer
J. Immunol., February 1, 2007; 178(3): 1268 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Huffman, M. S. Johnson, A. Watts, A. Elgavish, I. A. Eltoum, and T. R. Nagy
Cancer Progression in the Transgenic Adenocarcinoma of Mouse Prostate Mouse Is Related to Energy Balance, Body Mass, and Body Composition, but not Food Intake
Cancer Res., January 1, 2007; 67(1): 417 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Yu. Nikitina, S. A. Desai, X. Zhao, W. Song, A. Z. Luo, R. D. Gangula, K. M. Slawin, and D. M. Spencer
Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
Cancer Res., May 15, 2005; 65(10): 4309 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
Y. Tani, A. Suttie, G. P. Flake, A. Nyska, and R. R. Maronpot
Epithelial-Stromal Tumor of the Seminal Vesicles in the Transgenic Adenocarcinoma Mouse Prostate Model
Vet. Pathol., May 1, 2005; 42(3): 306 - 314.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
R. Mentor-Marcel, C. A. Lamartiniere, I. A. Eltoum, N. M. Greenberg, and A. Elgavish
Dietary Genistein Improves Survival and Reduces Expression of Osteopontin in the Prostate of Transgenic Mice with Prostatic Adenocarcinoma (TRAMP)
J. Nutr., May 1, 2005; 135(5): 989 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. W. Suttie, G. E. Dinse, A. Nyska, G. J. Moser, T. L. Goldsworthy, and R. R. Maronpot
An Investigation of the Effects of Late-Onset Dietary Restriction on Prostate Cancer Development in the TRAMP Mouse
Toxicol Pathol, April 1, 2005; 33(3): 386 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. K. Kolluri, M. Corr, S. Y. James, M. Bernasconi, D. Lu, W. Liu, H. B. Cottam, L. M. Leoni, D. A. Carson, and X.-k. Zhang
The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis
PNAS, February 15, 2005; 102(7): 2525 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. J. Baek, J.-S. Kim, S. M. Moore, S.-H. Lee, J. Martinez, and T. E. Eling
Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein
Mol. Pharmacol., February 1, 2005; 67(2): 356 - 364.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. K. Jain, S. M. Moore, K. Yamaguchi, T. E. Eling, and S. J. Baek
Selective Nonsteroidal Anti-Inflammatory Drugs Induce Thymosin {beta}-4 and Alter Actin Cytoskeletal Organization in Human Colorectal Cancer Cells
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 885 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Narayanan, N. K. Narayanan, B. Pittman, and B. S. Reddy
Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate Model
Clin. Cancer Res., November 15, 2004; 10(22): 7727 - 7737.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, and H. Mukhtar
Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model
Cancer Res., May 1, 2004; 64(9): 3334 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Tong and H.-H. Tai
Synergistic Induction of the Nicotinamide Adenine Dinucleotide-Linked 15-Hydroxyprostaglandin Dehydrogenase by an Androgen and Interleukin-6 or Forskolin in Human Prostate Cancer Cells
Endocrinology, May 1, 2004; 145(5): 2141 - 2147.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White
Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin
Cancer Res., March 1, 2004; 64(5): 1802 - 1810.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
R. E. Hill, D. M. de Avila, K. P. Bertrand, N. M. Greenberg, and J. J. Reeves
Immunization Against Luteinizing Hormone-Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer in the Transgenic Adenocarcinoma Mouse Prostate Model
Experimental Biology and Medicine, July 1, 2003; 228(7): 818 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. C. Desmond, J. C. Mountford, M. T. Drayson, E. A. Walker, M. Hewison, J. P. Ride, Q. T. Luong, R. E. Hayden, E. F. Vanin, and C. M. Bunce
The Aldo-Keto Reductase AKR1C3 Is a Novel Suppressor of Cell Differentiation That Provides a Plausible Target for the Non-Cyclooxygenase-dependent Antineoplastic Actions of Nonsteroidal Anti-Inflammatory Drugs
Cancer Res., January 15, 2003; 63(2): 505 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. Suttie, A. Nyska, J. K. Haseman, G. J. Moser, T. R. Hackett, and T. L. Goldsworthy
A Grading Scheme for the Assessment of Proliferative Lesions of the Mouse Prostate in the TRAMP Model
Toxicol Pathol, January 1, 2003; 31(1): 31 - 38.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
A. Nyska, A. Suttie, S. Bakshi, L. Lomnitski, S. Grossman, M. Bergman, V. Ben-Shaul, P. Crocket, J. K. Haseman, G. Moser, et al.
Slowing Tumorigenic Progression in TRAMP Mice and Prostatic Carcinoma Cell Lines Using Natural Anti-Oxidant from Spinach, NAO--A Comparative Study of Three Anti-Oxidants
Toxicol Pathol, January 1, 2003; 31(1): 39 - 51.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. F. Leitzmann, M. J. Stampfer, J. Ma, J. M. Chan, G. A. Colditz, W. C. Willett, and E. Giovannucci
Aspirin Use in Relation to Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1108 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. J. Baek, L. C. Wilson, C.-H. Lee, and T. E. Eling
Dual Function of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Inhibition of Cyclooxygenase and Induction of NSAID-Activated Gene
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1126 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Boutemmine, N. Bouchard, D. Boerboom, H. E. Jones, A. K. Goff, M. Dore, and J. Sirois
Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro
Endocrinology, March 1, 2002; 143(3): 1134 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
I. TEGEDER, J. PFEILSCHIFTER, and G. GEISSLINGER
Cyclooxygenase-independent actions of cyclooxygenase inhibitors
FASEB J, October 1, 2001; 15(12): 2057 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mentor-Marcel, C. A. Lamartiniere, I.-E. Eltoum, N. M. Greenberg, and A. Elgavish
Genistein in the Diet Reduces the Incidence of Poorly Differentiated Prostatic Adenocarcinoma in Transgenic Mice (TRAMP)
Cancer Res., September 1, 2001; 61(18): 6777 - 6782.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gupta, K. Hastak, N. Ahmad, J. S. Lewin, and H. Mukhtar
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols
PNAS, August 10, 2001; (2001) 171326098.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
S. D. Hursting, S. N. Perkins, L. A. Donehower, and B. J. Davis
Cancer Prevention Studies in p53-Deficient Mice
Toxicol Pathol, January 1, 2001; 29(1): 137 - 141.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gupta, K. Hastak, N. Ahmad, J. S. Lewin, and H. Mukhtar
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols
PNAS, August 28, 2001; 98(18): 10350 - 10355.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.